Fulcrum Therapeutics Stock Surges After Positive Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: MarketWatch
Fulcrum Therapeutics Inc's stock surged by 68.76% in pre-market trading, crossing above the 5-day SMA following encouraging results from its Phase 1b trial.
The company reported significant increases in fetal hemoglobin levels in the 20 mg dose cohort, with a 9.9% rise after six weeks of treatment. This promising data indicates a strong therapeutic potential for patients with sickle cell disease, enhancing investor confidence.
As Fulcrum prepares to present updated trial results in Q1 2026, the positive outcomes from the trial could solidify its market position and attract further investment in its innovative treatments.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 16.80 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.480
Low
7.00
Averages
16.80
High
25.00
Current: 10.480
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
